Cidofovir

An antiviral agent and active metabolite of brincidofovir

Cidofovir is an acyclic nucleoside phosphonate antiviral agent and an active metabolite of brincidofovir (Item No. 35062).1 It is formed from brincidofovir in MRC-5 human lung fibroblasts. Cidofovir inhibits CMV DNA synthesis in a cell-free assay, as well as replication of two CMV strains in plaque formation assays (IC50s = 0.1 and 0.07 µg/ml for Davis and AD-169 strains, respectively).2,3 It decreases mortality in mouse models of cowpox or vaccinia virus infections when administered at a dose of 15 mg/kg.4 Formulations containing cidofovir have been used in the treatment of CMV retinitis in patients with AIDS.

279.2

≥95%

(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine|(S)-HPMPC|GS-0504

NC(C=CN1C[C@H](OCP(O)(O)=O)CO)=NC1=O

C8H14N3O6P

113852-37-2

≥ 4 years

PBS (pH 7.2): 2 mg/ml

1.Snoeck, R.,Sakuma, T.,De Clercq, E., et al. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrobial Agents and Chemotherapy 32(12), 1839-1844 (1988).
2.Connelly, M.C.,Robbins, B.L. and Fridland, A. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine (HPMPC) in vero cells. Biochemical Pharmacology 46(6), 1053-1057 (1993).
3.De Clercq, E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin.Microbiol.Rev. 16(4), 569-596 (2003).